This highly anticipated drug is expected to become a key treatment for prurigo nodularis and atopic dermatitis. Galderma’s midterm targets for the period 2023 to 2027 are for low- to mid-teens ...

As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.

Kendall has over 18 years of extensive pharmaceutical industry experience across sales, marketing, and leadership roles in ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial ...

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth.

Shares of AbbVie Inc. ABBV inched 0.10% higher to $173.37 Friday, on what proved to be an all-around mixed trading session ...

Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...

AbbVie ( ) has shared an update. AbbVie announced the retirement of Kevin K. Buckbee from his role as Senior Vice President, Controller, effective March 1, 2025, and the appointme ...